Carola Wolber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carola Wolber has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Astrid Udvardi
Sozialmedizinische Zentrum Ost, Donauspital
3 shared publicationsAchim Schneeberger
Universitätsklinik für Dermatologie, Abteilung für Immundermatologie
2 shared publicationsGeorg Tatzreiter
Donauspital SMZ Ost, II. Medizinische Abteilung
2 shared publicationsBeatrix Volc-Platzer
Donauspital SMZ Ost, Abteilung für Dermatologie und Venerologie
1 shared publicationBeatrix Volc‐Platzer
Donauspital SMZ Ost, Department of Dermatology and Venereology, Vienna, Austria
1 shared publication- Beatrix Volc‐Platzer
College of Physicians in Vienna, Vienna, Austria
1 shared publication
Latest Publications
- 1 April 2011
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 161 (7-8) , 204-208
Sacroileitis im Rahmen eines SAPHO Syndroms – promptes Ansprechen auf Etanercept
- 1 April 2011
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 161 (7-8) , 204-208
Sacroileitis im Rahmen eines SAPHO Syndroms – promptes Ansprechen auf Etanercept
- 1 May 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (5) , 449-452
Perforierende Follikulitis, Angioödem, Hand-Fuß-Syndrom – multiple kutane Nebenwirkungen bei einem Patienten unter Sorafenib
- 1 May 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (5) , 449-452
Perforierende Follikulitis, Angioödem, Hand-Fuß-Syndrom – multiple kutane Nebenwirkungen bei einem Patienten unter Sorafenib
- 16 April 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (5) , 449-451
Perforating folliculitis, angioedema, hand‐foot syndrome – multiple cutaneous side effects in a patient treated with sorafenib
Summary: A patient with clear cell renal cell carcinoma was treated with sorafenib, a multikinase inhibitor, which induced a variety of cutaneous side effects. In addition to xerosis, he developed angioedema (AE), hand‐foot syndrome (HFS) and perforating folliculitis (PF). The latter three occurred in a dose‐dependent manner. AE was observed at the recommended daily dose of 800 mg. Dose reduction to 400 mg prevented its recurrence. At this dose level, the patient exhibited HFS, which cleared upon further reduction of the dose. While receiving 200 mg, the patient developed PF. To the best of our knowledge, this is the first description of a case of PF during treatment with sorafenib.
- 16 April 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (5) , 449-451
Perforating folliculitis, angioedema, hand‐foot syndrome – multiple cutaneous side effects in a patient treated with sorafenib
Summary: A patient with clear cell renal cell carcinoma was treated with sorafenib, a multikinase inhibitor, which induced a variety of cutaneous side effects. In addition to xerosis, he developed angioedema (AE), hand‐foot syndrome (HFS) and perforating folliculitis (PF). The latter three occurred in a dose‐dependent manner. AE was observed at the recommended daily dose of 800 mg. Dose reduction to 400 mg prevented its recurrence. At this dose level, the patient exhibited HFS, which cleared upon further reduction of the dose. While receiving 200 mg, the patient developed PF. To the best of our knowledge, this is the first description of a case of PF during treatment with sorafenib.